Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2011Circulation JournalOpen Access

Antithrombotic Therapy in Atrial Fibrillation - Evaluation and Positioning of New Oral Anticoagulant Agents -

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Do new oral anticoagulants, specifically dabigatran, prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation compared to warfarin?

Population

Patients with nonvalvular atrial fibrillation (NVAF)

Comparison

New oral anticoagulants, specifically dabigatran vs Warfarin

Design

Review

Authors

SOSatoshi OgawaNational Institute of Technology, Niihama CollegeYKYukihiro KoretsuneUniversity of ShizuokaMYMasahiro YasakaOhkawara Neurosurgical Hospital

Discussion

Loading...

Member takes

Implication

May support dabigatran as alternative to warfarin in nonvalvular AF; leaves open comparative trials among NOACs.

Structured PICO

Do new oral anticoagulants, specifically dabigatran, prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation compared to warfarin?

P
Population
Patients with nonvalvular atrial fibrillation (NVAF)
I
Intervention
New oral anticoagulants, specifically dabigatran
C
Comparator
Warfarin
O
Outcome
Prevention of stroke and systemic embolismhard clinical

New oral anticoagulants, particularly dabigatran, offer a viable, effective, and safer alternative to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation without the need for routine coagulation monitoring.

Cite This Study

Ogawa et al. (2011) studied this question.

synapsesocial.com/papers/6a2214142e065aea6049359fhttps://doi.org/10.1253/circj.cj-11-0304

Topics

Atrial fibrillationAnticoagulation in AFPersistent AF management
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran2003 · 456 citations
  2. 2Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Rivaroxaban—an Oral, Direct Factor Xa Inhibitor—Are Not Affected by Aspirin2006 · 182 citations
  3. 3New oral anticoagulants in development2009 · 104 citations
  4. 4Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation2007 · 4,830 citations
  5. 5Dabigatran versus Warfarin in Patients with Atrial Fibrillation2009 · 11,282 citations